Clinical Trials Logo

Clinical Trial Summary

A Phase II Randomized,Controlled,Open Label,Multicentre Study to evaluate the efficacy and safety of Tegafur combined with Temozolomide versus Tegafur combined with Temozolomide and Thalidomide in subjects with Advanced Pancreatic Neuroendocrine Tumor


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03204019
Study type Interventional
Source Chinese Academy of Medical Sciences
Contact Yihebali Chi, doctor
Email dryihebalichi@126.com
Status Recruiting
Phase Phase 2
Start date October 2016
Completion date September 2018

See also
  Status Clinical Trial Phase
Recruiting NCT05566093 - EUS-FNI for Nonfunctional Pancreatic Neuroendocrine Tumors N/A
Completed NCT00970970 - Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease N/A
Recruiting NCT05568017 - Neoadjuvant PRRT With Y-90-DOTATOC in pNET Phase 2
Not yet recruiting NCT06024343 - Minimally Invasive Pancreatic Enucleation With Main Pancreatic Duct Repair or Reconstruction N/A
Recruiting NCT03891784 - Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors Phase 2
Completed NCT00804336 - Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors Phase 1
Recruiting NCT05997056 - Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors Phase 2
Not yet recruiting NCT06158516 - A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors Phase 2
Recruiting NCT04119024 - Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma Phase 1
Recruiting NCT05040360 - Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors Phase 2
Not yet recruiting NCT05988918 - Multicenter Trial of ESK981 in Patients With Select Solid Tumors Phase 2
Completed NCT00576680 - RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors Phase 1/Phase 2
Recruiting NCT05610826 - Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver Phase 1/Phase 2
Active, not recruiting NCT03074513 - Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors Phase 2
Completed NCT03967951 - CT Radiomic Features of Pancreatic Neuroendocrine Neoplasms
Completed NCT01024387 - AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors Phase 2
Not yet recruiting NCT03435770 - Evaluation of Safety and Feasibility of EUS-guided RFA for Solid Pancreatic Neoplasms N/A
Recruiting NCT04134832 - Study of Pancreatic Neuroendocrine Tumors and Carcinomas in Alsace Region
Recruiting NCT05554744 - EUS-FNI for MEN1-related Pancreatic Neuroendocrine Tumors N/A
Completed NCT02159989 - Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Phase 1